Literature DB >> 24383473

Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.

N Ali1, S N Adil, M U Shaikh.   

Abstract

INTRODUCTION: Bloodstream infections (BSIs) and central line infections remain among the major causes of morbidity and mortality in transplant recipients because of prolonged neutropenia and mucosal damage. The objective of this study was to determine the frequency and outcome of bacterial and fungal isolates from patients undergoing allogeneic hematopoietic stem cell transplant.
MATERIALS AND METHODS: This study was conducted at the Aga Khan University and Hospital's bone marrow transplant unit. All patients who underwent an allogeneic stem cell transplant with matched sibling/parent donor were included. The study period ranged from April 2004 to December 2012. Transplantation was performed according to institutional protocols. All patients were admitted in single rooms with positive pressure and high-efficiency particulate air filters. Ciprofloxacin, fluconazole, and valaciclovir were used for standard prophylaxis, which was started at the time of conditioning. All blood cultures were obtained at clinical suspicion of systemic infection, mainly documented as fever (temperature of >38.5°C). BSIs and line infections were defined as isolation of bacterial or fungal pathogen from at least one blood/central line culture.
RESULTS: In total, 101 of 108 patients developed febrile neutropenia. In the 101 patients, 245 documented febrile episodes occurred. There were 40 culture-positive episodes and 205 culture-negative episodes. Of these 40 culture-positive episodes, 22 patients had bloodstream isolates and 18 had central line isolates. The median ± standard deviation time of febrile neutropenia was day 7 ± 2 days (range: day -3 to day +13). The most common bloodstream isolate was Escherichia coli (n = 9) followed by Staphylococcus epidermidis (n = 5). One patient developed Fusarium infection. In central line infections, S. epidermidis was the most common organism (n = 8). In 2 patients with central venous catheters, Candida albicans was the isolate. Transplant-related mortality from sepsis occurred in 9.2%.
CONCLUSION: E.coli was mainly responsible for BSI, while gram-positive organisms dominated catheter-related febrile episodes. Transplant-related mortality due to sepsis was 9%.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BSI; CLABSI; E. coli; bloodstream infection; central line infection

Mesh:

Substances:

Year:  2014        PMID: 24383473     DOI: 10.1111/tid.12176

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  4 in total

1.  Profile and Antibiotic Pattern of Blood Stream Infections of Patients Receiving Hematopoietic Stem Cell Transplants in Southwest China.

Authors:  Qiang Zeng; Bing Xiang; Zhigang Liu
Journal:  Infect Drug Resist       Date:  2022-04-21       Impact factor: 4.177

2.  Bacteremia in Hematopoietic Stem Cell Recipients Receiving Fluoroquinolone Prophylaxis: Incidence, Resistance, and Risk Factors.

Authors:  Esma Eryilmaz-Eren; Feyza Izci; Zeynep Ture; Pinar Sagiroglu; Leylagul Kaynar; Aysegul Ulu-Kilic
Journal:  Infect Chemother       Date:  2022-07-29

3.  The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Mücahit Yemişen; İlker İnanç Balkan; Ayşe Salihoğlu; Ahmet Emre Eşkazan; Bilgül Mete; M Cem Ar; Şeniz Öngören; Zafer Başlar; Reşat Özaras; Neşe Saltoğlu; Ali Mert; Burhan Ferhanoğlu; Recep Öztürk; Fehmi Tabak; Teoman Soysal
Journal:  Turk J Haematol       Date:  2015-05-04       Impact factor: 1.831

4.  Early infection in post-autologous hematopoietic stem cell transplant patients: Princess Noorah Oncology Center experience.

Authors:  Roaa S Gassas; Ahmed N Absi; Abdulrahman A Alghamdi; Ahmed S Alsaeed; Sameer M Alamoudi; Ihab Y Hemaidi; Majed D Alahmadi; Walaa A Rajkhan; Mannar M Khalil; Saleem K Dadah; Ahmed S Higazi; Amani S Ahmed
Journal:  Saudi Med J       Date:  2021-08       Impact factor: 1.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.